Home PMWS News PMWS Research PMWS Forum PMWS Newsletter
PCVD.org Dansk
PCVD.org Franįais
PCVD.org Svenska
PCVD.org Nederlands
PCVD.org Espaņol
PCVD.org English


This free resource is kindly supported by: If you have a information you would like is to include in this section please contact us

Vaccination
Management
Disease Information
A PMWS update (Jake Waddilove)
ABOUT PMWS & PDNS
National Pork Board PMWS Fact Sheet
About PDNS (Jake Waddilive)
CEI Emerging Disease Notices: PMWS / PDNS
Conference and meetings archive
Case Histories
Yorkshire Farm, UK - Mike Muirhead - Final Update, June 2002
Mike Muirhead's case history of a Yorkshire farm with PMWS and PDNS.
 
East Anglia Farm, UK - Philip Richardson
This paper charts the course and effects of the disease on a single herd as well as highlighting the economic impact.
Photographs
Clinical signs
Photos of the clinical signs that are seen generally in pigs with PMWS and PDNS. Includes skin lesions, enlarged lymph glands, wasting and dead pigs.
 
Post mortem (1)
Photos of the signs that are seen in post-mortem samples of pigs with PMWS and PDNS. Includes interstitial pneumonia, secondary bacterial infection, enlarged lymph nodes, oedema and intra cytoplasmic inclusions
 
Post mortem (2)
More Photos of the signs that are seen in post-mortem samples of pigs with PMWS and PDNS.


PMWS Research Archives

Published Friday, December 01, 2006: J Swine Health Prod 2006;14(3):133-139
Effects of adjuvants on porcine circovirus type 2-associated lesions
Marlin J. Hoogland, DVM, MS; Tanja Opriessnig, Dr med vet; Patrick G. Halbur, DVM, PhD
Objective: To determine if adjuvants differ in their ability to trigger lesions associated with porcine circovirus type 2 (PCV2).
Methods: Ninety pigs randomly assigned to five groups were vaccinated intramuscularly at 4 and 6 weeks of age with 2 mL of a commercial Mycoplasma hyopneumoniae (M hyo) vaccine with oil-in-water adjuvant (Group 1), a commercial M hyo vaccine with an aqueous-carbopol adjuvant (Group 2), an experimentally produced M hyo vaccine with an oil-in-water adjuvant (Group 3), or an experimentally produced M hyo vaccine with an aluminum hydroxide adjuvant (Group 4), or were sham-vaccinated with saline (Group 5). All pigs were inoculated intranasally at 6 weeks of age with PCV2 (Day 0). Half of the pigs were necropsied at Day 21 and the remaining pigs at Day 35.
Results: No clinical disease was observed in any pigs during this study. At Day 21, lymphoid depletion was more severe in all M hyo-vaccinated pigs than in the saline-treated pigs (P < .05). At Day 35, greater amounts of PCV2 DNA were found in serum, more severe lymphoid lesions were observed, and more PCV2 antigen was detected in lymphoid tissues in Groups 1 and 3 (oil-in-water adjuvant) compared to Groups 2, 4, and 5 (P < .05).
Implications: Under the conditions of this study, oil-in-water adjuvanted vaccines are more likely to enhance PCV2-associated lesions than aqueous-carbopol or aluminium hydroxide adjuvanted vaccines. Practitioners must weigh benefits and efficacy of vaccines intended to control coinfections against the potential negative effect certain vaccines may have on PCV2 replication.

To continue reading this article please click here

Have you published information? To add please email the details

pcvd Merial BPEX PMWS, PCVD Technical Zone home page

Friday 5th December

Our Main Sponsors
 
Supporting Partners